Stockreport

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® [Yahoo! Finance]

Valneva SE - American Depositary Shares  (VALN) 
PDF Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya Saint-Herblain (France), Septem [Read more]